ClinicalTrials.Veeva

Menu

Safety and Efficacy of AGN201781 in Neuropathic Pain

Allergan logo

Allergan

Status and phase

Terminated
Phase 2

Conditions

Neuralgia

Treatments

Drug: AGN201781
Drug: placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00533351
201781-504

Details and patient eligibility

About

This study will explore the safety and efficacy of AGN201781 in patients with postherpetic neuralgia or post-traumatic peripheral neuralgia

Enrollment

9 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia
  • Moderate or severe pain associated with postherpetic neuralgia or post-traumatic peripheral neuralgia

Exclusion criteria

  • Women of child-bearing potential
  • Any other uncontrolled diseases

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

9 participants in 2 patient groups, including a placebo group

AGN201781
Experimental group
Description:
AGN201781 50 mg capsules three-time daily for 2 weeks
Treatment:
Drug: AGN201781
Placebo
Placebo Comparator group
Description:
placebo 50 mg capsules three-times daily for 2 weeks
Treatment:
Drug: placebo

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems